GH Research (GHRS) Exchange Rate Effect (2020 - 2026)
GH Research (GHRS) posted quarterly Exchange Rate Effect of $155000.0 for Q4 2025, up 264.89% year-over-year from $42478.1 in Q4 2024, and up 160.78% quarter-over-quarter from -$255000.0 in Q3 2025.
Powered by 
Analysis
GH Research (GHRS) Exchange Rate Effect (2020 - 2026) Analysis & Trends
GH Research's Exchange Rate Effect history runs 6 years deep, the most recent figure standing at $155000.0 for Q4 2025.
- In Q4 2025, Exchange Rate Effect rose 264.89% year-over-year to $155000.0; the TTM figure through Dec 2025 stood at $3.2 million (up 1922.29% YoY), while the FY2025 annual figure was $3.2 million, up 1922.29% from the prior year.
- Exchange Rate Effect for Q4 2025 stood at $155000.0, up from -$255000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $3.2 million in Q2 2025, with the low at -$378000.0 in Q3 2022.
- The 5-year median for Exchange Rate Effect is -$18000.0 (2021), against an average of $150300.0.
- The sharpest annual moves came in 2022 and 2025: Exchange Rate Effect tumbled 2420.0% in 2022, then jumped 9655.88% in 2025.
- GH Research's Exchange Rate Effect stood at -$21000.0 in 2021, then soared by 2585.71% to $522000.0 in 2022, then tumbled by 74.9% to $131000.0 in 2023, then tumbled by 171.76% to -$94000.0 in 2024, then jumped by 264.89% to $155000.0 in 2025.
- Business Quant data shows GHRS's Exchange Rate Effect at $155000.0 in Q4 2025, -$255000.0 in Q3 2025, and $3.2 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - | -789,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -789,000.00 |
| Mar 31, 2026 | -1.57 Mn |
| Dec 31, 2025 | 155,000.00 |
| Sep 30, 2025 | -255,000.00 |
| Jun 30, 2025 | 3.25 Mn |
| Mar 31, 2025 | 40,000.00 |
| Dec 31, 2024 | -94,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Jun 30, 2024 | -34,000.00 |
| Mar 31, 2024 | -58,000.00 |
| Dec 31, 2023 | 131,000.00 |
| Sep 30, 2023 | -52,000.00 |
| Jun 30, 2023 | -78,000.00 |
| Mar 31, 2023 | 104,000.00 |
| Dec 31, 2022 | 522,000.00 |
| Sep 30, 2022 | -378,000.00 |
| Jun 30, 2022 | -63,000.00 |
| Mar 31, 2022 | -15,000.00 |
| Dec 31, 2021 | -21,000.00 |
| Sep 30, 2021 | -15,000.00 |